Year: 2026
Type: preprint
Abstract: Biobanked tissue samples are essential for cancer research, yet pre-analytical ischemia–hypoxia during tissue handling can compromise tissue or derived models’ quality, limiting their value for translational research. Here, we investigated whether M101, an extracellular hemoglobin from Arenicola marina , could mitigate indirectly by providing oxygen handling-induced ischemia–hypoxia in cancer tissues and subsequent live 3D models. Using prostate cancer PC3 and ovarian cancer TOV-21G xenografted tumors preserved ex vivo , M101 reduced the emergence of hypoxia-associated markers, including the hypoxia-inducible factor 1-alpha, and attenuated metabolic stress. In xenograft-derived micro-dissected 3D tumor models cultured for 8 days, M101 improved tissue morphology, reduced fragmentation, and was associated with higher proliferative activity and lower inflammatory interleukin-6 release. Together, these findings suggest that M101 helps preserve structural and functional features of biobanked tumor models during ex vivo handling. Thus, oxygen carriers could represent a bio-compatible strategy to improve the fidelity of biobanked samples and patient-derived tumor models for precision oncology applications.
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
Funders: Cancer Research Society, Québec Consortium for Drug Discovery, Ovarian Cancer Canada, Terry Fox Research Institute, Mitacs, Université de Montréal, Fonds de recherche du Québec, Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Institute of Cancer Research
Awards: G13466328, G6354638321, G8287423649
OpenAlex ID: W7234395599
